BLRX News
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayPR NewswireTEL AVIV, Israel...
PR Newswire
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayPR NewswireTEL AVIV, Israel...
PR Newswire
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a...
PR Newswire
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, Aug. 31, 2026 - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third...
PR Newswire
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement PR Newswire TEL AVIV, Israel, Aug. 28, 2026 TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd...
PR Newswire
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 PR Newswire TEL AVIV, Israel, Aug. 25, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd...
PR Newswire
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO...
PR Newswire
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and...
PR Newswire
BioLineRx (BLRX) Q1 2026 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2026 - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of...
PR Newswire
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire TEL AVIV, Israel and OSLO...
PR Newswire